Skip to main content
Clinical Trials/NCT01586663
NCT01586663
Unknown
Phase 3

Evaluation of Serial Night Time Position Splint on Range of Motion for Patients With Systemic Sclerosis

Federal University of São Paulo1 site in 1 country76 target enrollmentStarted: January 2010Last updated:

Overview

Phase
Phase 3
Sponsor
Federal University of São Paulo
Enrollment
76
Locations
1
Primary Endpoint
Change in hand range of motion

Overview

Brief Summary

This is a randomized controlled trial with blinded evaluator and follow-up of one year. Seventy six patients with diffuse systemic sclerosis, will be randomized into two groups.The patients can not change their medication during the study. Patients will be evaluated at baseline and at 3, 6, 9 and 12 months. The experimental group will use a serial night time position splint who will be adjusted monthly, while the control group will remain the drug treatment. The outcomes assessed will be: pain, hand range of motion, quality of life, functional capacity, upper limb function and dexterity. Our hypothesis is that the serial night time position splint will improve the hand range of motion in diffuse systemic sclerosis patients.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diffuse Systemic scleroses diagnosed following the ACR criteria
  • Older than 18 years old
  • Sclerodactyly

Exclusion Criteria

  • Neurological, psychiatric diseases and other rheumatic disease (including overlapping)
  • Previous use of splints or allergy to splint material
  • Surgery schedule to the next 12 months

Arms & Interventions

Experimental Group

Experimental

Splint group

Intervention: Serial night time position splint (Device)

Control Group

Active Comparator

Drug treatment

Intervention: Drug treatment (Drug)

Outcomes

Primary Outcomes

Change in hand range of motion

Time Frame: Baseline and after 3, 6, 9 and 12 months

Measured by goniometry

Secondary Outcomes

  • Change in pain(Baseline, after 10, 20 and 40 weeks)
  • Change in functional capacity(Baseline, after 10, 20 and 40 weeks)
  • Change in quality of life(Basline, after 10, 20 and 40 weeks)
  • Change in upper limb function(Baseline, after 10, 20 and 40 weeks)
  • Change in dexterity(Baseline, after 3, 6, 9 and 12 months)

Investigators

Sponsor
Federal University of São Paulo
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Fernanda Pontes Cardoso

Principal Investigator

Federal University of São Paulo

Study Sites (1)

Loading locations...

Similar Trials